Kestra Medical Technologies (KMTS) Capital Expenditures (2024 - 2026)

Kestra Medical Technologies (KMTS) has 3 years of Capital Expenditures data on file, last reported at $9.8 million in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $9.8 million, up 205.75% year-over-year; the trailing twelve-month figure through Jan 2026 was $24.9 million (up 293.16% YoY), and the FY2025 annual result was $1.9 million, down 84.66% from the prior year.
• Capital Expenditures advanced to $9.8 million in Q1 2026 per KMTS's latest filing, from $7.3 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $9.8 million in Q1 2026 and troughed at -$9.3 million in Q1 2025.
• A 3-year average of $3.9 million and a median of $5.7 million in 2024 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2025 and 2026: Capital Expenditures sank 108.4% in 2025, then jumped 205.75% in 2026.
• A 3-year view of Capital Expenditures shows it stood at $4.4 million in 2024, then jumped by 63.37% to $7.3 million in 2025, then surged by 34.85% to $9.8 million in 2026.
• Business Quant data shows KMTS's Capital Expenditures at $9.8 million in Q1 2026, $7.3 million in Q4 2025, and $8.2 million in Q3 2025.